Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05015348
Other study ID # HS-2908
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date January 31, 2022

Study information

Verified date August 2021
Source Peking Union Medical College Hospital
Contact Kang Yu, master
Phone +8613801130457
Email yuk1997@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with hyperlipidemia will be allocated into intervention or control group randomly. Participants of intervention group will be provided with Omega-3 PUFA, while participants of control group will be provided with placebo which looked same as the drug of intervention group. During the study, all participants can have nutritional counseling and education for low-fat diet. The lipids, inflammatory factors, weight, and body composition will be assessed and recorded before, at the middle, and end of the study.


Description:

Randomization tables were generated by the statistician and provided to the investigational pharmacist who distributed the blinded pills to participants. Participants of intervention group will be provided with Omega-3 PUFA, while participants of control group will be provided with placebo which looked same as the drug of intervention group. During the study, all participants can have nutritional counseling and education for low-fat diet. The lipids, inflammatory factors, weight, and body composition will be assessed and recorded before, at the middle, and end of the study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date January 31, 2022
Est. primary completion date December 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - [1] Gender and age: male or female, 18 years old and above. - [2] Patients were diagnosed with hyperlipidemia. According to the definition of 2016 guidelines for the prevention and treatment of dyslipidemia in Chinese adults, it meets the clinical diagnostic criteria of hyperlipidemia: hypertriglyceridemia [TG=1.7mmol/L]; Or mixed with TC=5.2mmol/L]; Or mixed with LDL-C=3.4mmol/L]. - [3] Before the study, the subjects fully understood and voluntarily signed the informed consent form, and fully understood the research content, process and possible adverse reactions. - [4] Those who can eat orally. - [5] Be able to complete the research according to the requirements of the research protocol and obey the arrangements of doctors and researchers. Exclusion Criteria: - [1] Those who are receiving lipid-lowering drugs. - [2] Hyperlipidemia caused by secondary causes, such as nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, glycogen accumulation, myeloma, fat atrophy, acute porphyria, polycystic ovary syndrome, etc; Use diuretics, non cardiac selective ß Receptor blockers and glucocorticoids which may cause secondary dyslipidemia. - [3] Patients with severe internal and external diseases, such as heart, liver and kidney dysfunction, acute myocardial infarction, stroke, intracerebral hemorrhage, acute attack of COPD, respiratory failure, etc. in recent 3 months, patients who have undergone surgery in recent 3 months, or any person who is not suitable to participate in this study after clinician evaluation. - [4] Have hemorrhagic disease or bleeding tendency. - [5] Those who have a history of allergy to omega-3 polyenoic acid preparation. - [6] Pregnant and lactating women. - [7] Poor compliance, unable to follow up on time or unable to complete the follow-up of medication. - [8] In the course of diagnosis and treatment, if there is any seriously abnormal metabolism or further intervention is needed, or the patient is no longer suitable for continuing the study through the assessment of the competent physician, he can withdraw from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
fish oil with omega-3 PUFA
3.6g per day fish oil with omega-3 PUFA (EPA+DHA)
placebo
palm oil as placebo

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary triglyceride triglyceride in mmol/L 3 months
Primary cholesterol cholesterol in mmol/L 3 months
Primary LDL-C LDL-C in mmol/L 3 months
Primary TNF-a TNF-a in ng/ml 3 months
Primary NF-?B NF-?B in ng/ml 3 months
Primary hsCRP hsCRP in mmol/L 3 months
Primary interlukin-6 IL-6 in ng/ml 3 months
Primary body weight weight in kilogram 3 months
Primary BMI BMI in kg/m2 3 months
Secondary adiponectin adiponectin in µg/mL 3 months
Secondary leptin leptin in µg/mL 3 months
See also
  Status Clinical Trial Phase
Completed NCT03793985 - Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 Phase 1
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Completed NCT04516291 - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Phase 2
Completed NCT03632668 - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 Phase 1
Completed NCT04701775 - Effect of Different Probiotic Strains in Hypercholesterolemic Patients N/A
Completed NCT03534661 - L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release Phase 2/Phase 3
Completed NCT03422666 - Plasma Lipoprotein Response to Glucagon-like Peptide-2 Phase 2/Phase 3
Completed NCT00536796 - Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Recruiting NCT04560296 - Community-based E-Health Program for Older Adults Living With Chronic Diseases N/A
Terminated NCT04073134 - The CHORAL Flow Study Phase 4
Recruiting NCT05103254 - Bempedoic Acid Pregnancy Surveillance Program
Active, not recruiting NCT05082350 - Nutritional Intervention With Black Garlic N/A
Not yet recruiting NCT04398771 - To Evaluate Safety and Effectiveness of RovatitanTab.
Not yet recruiting NCT04064281 - The Healthy Cantonese Diet on Cardiometabolic Syndrome N/A
Recruiting NCT06257641 - Impact of the Mediterranean Diet on Patients With Psoriasis N/A
Completed NCT03690778 - The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers. Phase 1
Completed NCT04354987 - Compare the Pharmacokinetics and Safety of CKD-391 Phase 1
Completed NCT03337308 - A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy Phase 3